Answers are grounded in this paper and cite their sources.
Shows effective PSA decline in mHSPC patients, indicating strong treatment benefits.
e17094 Background: Data from the Titan Trial (apalutamide + ADT) showed a benefit for mHSPC patients who achieved low ( < 0.2 ng/ml) and ultra-low (UL-1 0.02–0.2 ng/ml / UL-2 < 0.02 ng/ml) PSA levels under apalutamide (APA) therapy. The AmPel study (Use of Apalutamide in Prostate Cancer in Middle-Hesse) has been collecting data from mHSPC patients in urology practices since November 2021. Methods: In this multicenter investigator initiated trial (IIT), patient data (demographic and tumor-specific) as well as outcomes (PSA response/course including UL ( < 0.2 ng/ml), UL-1 (0.02-0.2 ng/ml), UL-2 ( < 0.02 ng/ml)), side effects, and dose modifications are recorded. A positive approval from the ethics committee is available. Results: 127 pat (73 y, range 43-87, ECOG 0/1/2/3: 33.1/50.4/9.4/4.7%) were documented from 9 specialized urology practices (med FU 14 months). Synchronous mHSPC was present in 67.7%, an initial Gleason score ≥ 8 was observed in 65.3%, high-volume mHSPC in 56.7%, and the median PSA before starting APA was 15.4 ng/ml. After 3 months PSA decreased by 98.5% and after 12 months by 99.5%. There was no PFS difference neither in older pat ( > 75 years, p = 0.46) nor in case of dose reduction (15%) of APA (p = 0.7). After 12 months, 32.6% of pat reached a UL-2 PSA and nearly the same number (31.6%) reached a UL-1 PSA. There was a significant PFS advantage for UL-1 PSA (HR 0.28) and UL-2 PSA (HR 0.06). In the overall cohort, PFS has not been reached yet. Currently, 77.2% are still receiving APA. In 22.8% treatment was discontinued after a median of 8 months: in 9.4% due to progression. Overall, 7 pat died – 2 (1.6%) due to PCA. Conclusions: Our Real World Data show that APA therapy is highly effective in mHSPC and achieving UL-PSA quickly and sustainably (64.2% after 12 months) as well as PSA decrease of > 95% (91.6% after 12 months) - associated with significantly improved PFS in an unselected patient population and good tolerability in daily practice.
No takes yet. Share an insight, caveat, or question.
Hegele et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: